This post was originally published on this site
Despite continued inflationary pressures, the second quarter “yielded promising outcomes for the leading 20 biopharmaceutical giants,” said the firm.
GlobalData analysts said Eli Lilly & Company (NYSE:LLY) witnessed the largest market capitalization growth of 36.1% over Q2 2023. It moved up to first position in the list, “displacing Johnson & Johnson from its top spot for the first time even though it reported a 6.8% increase in market capitalization.”
LLY’s strong market capitalization growth was said to have been driven by its diabetes drug Mounjaro.
Meanwhile, Merck (NYSE:MRK) rose to third position with an 8.4% market capitalization increase due to its $10.8 billion acquisition of Prometheus Biosciences.
“This strengthens Merck & Co’s immunology pipeline with the addition of PRA023 – a monoclonal antibody drug currently being evaluated in ulcerative colitis, Crohn’s disease, and systemic sclerosis – which is forecasted to achieve global sales of $2.1 billion by 2029,” GlobalData stated.
Despite the rise in some names, more than half of the top 20 reported a decline in their market capitalization over Q2 2023. For example, AbbVie (NYSE:ABBV) declined by -15.5%, while Pfizer’s (NYSE:PFE) fell by -10.1%.
The analysts added that biopharmaceutical companies such as AbbVie are “starting to experience the consequences of biosimilar competition.”
